July 5, 2023 4:53pm
Opportunity is co-dependent on the paucity of news, upcoming net Q2 losses and depreciating runway’s
Subscription is coming, it is not conscription but, an offer to join our collective of like-minded investors! Join me … in the NO spin zone.
Never leave an investor uninformed!
Framing the main takeaway … pricing, volume and machine trading creates volatility and liquidity!
If I have learned one thing as a former research analyst in a venture and public fund, operating executive, adjunct (MBA) business school professor now a journalist; it is that your life and your portfolio are largely tied to your knowledge of price movements and questioning pricing targets.
The Dow closed DOWN -129.83 points (-0.38%), the S&P closed DOWN -6.77 points (-0.20%) while the Nasdaq closed DOWN -25.12 points (-0.18%)
Henry’omics:
We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies …
The Dow, S&P and Nasdaq dumped as I believe – who’s working post the holiday; I am watching indexes and the sector in between moving mulch and loam after suffer a slight back issue (last week) – I refuse to be a cripple, lazy and unable to work in the yard or write.
“Investors parsed minutes from the June 13-14 Fed meeting released Wednesday afternoon, in which most officials indicated further interest rate hikes could lie ahead.” <CNBC>
Brace for jobs report on Friday!
Economic Data Docket: factory orders were weaker than expected in May. Later in the week, investors will watch for a batch of employment and wage data for insights into the strength of the labor market.
Wednesday (7/5) … RegMed Investors’ (RMi) pre-open: “Welcome to Q3, are you feeling lucky? Electronic trading, speculation and volatility still lurk; is a summer slowdown coming, or will it just keep stay on the roller-coaster?” … https://www.regmedinvestors.com/articles/13029
RegMed/Stem/Cell and Gene Therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened – differences …
- Wednesday’s advance/decline line opened negative at 10 up/ 23 down and 2 flats, stayed negative with 11 up/ 21 down and 3 flats at the mid-day, ending with a negative close of 12 incliners, 20 decliners and 3 flats
- Tuesday was a holiday
- Monday was a vacation day; advance/decline line opened positive at 20 up/ 14 down and 1 flat, stayed positive with 17 up/ 15 down and 2 flats at the mid-day, ending with a positive close of 20/213 and 1 flat
Key Metrics:
The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:
- Wednesday the IBB was up +0.17% and the XBI was up +0.10%
- Tuesday, holiday
- Monday, vacation; the IBB was down -0.12% and the XBI was down -0.31%
The CBOE Volatility Index (VVIX: INDEX) tracked:
- Wednesday was up +0.44 point or +3.21% at 14.14
- Tuesday was holiday
- Monday was vacation day, was down -0.02 point or -0.05% at 13.57
Closing Down (10 of 20):
- Blueprint Medicine (BPMC -$1.29)
- Vericel (VCEL -$1.15),
- BioLife Solutions (BLFS -$1.10),
- Sage Therapeutics (SAGE -$1.03),
- Regenxbio (RGNX -$0.81),
- Verve therapeutics IVERV -$0.34),
- AxoGen (AXGN -$0.26),
- Intellia Therapeutics (NTLA -$0.26),
- Ultragenyx (RARE -$0.23),
- Voyager Therapeutics (VYGR -$0.20)
Flat (2):
- Adverum Biotechnologies (ADVM)
- Biostage (OTCQB: BSTG)
- Precigen (PGEN)
Closing Up (10 of 12):
- Alnylam Pharmaceuticals (ALNY +$2.88),
- Ionis Pharmaceuticals (IONS +$1.11),
- CRISPR Therapeutics (CRSP +$0.53),
- Prime Medicine (PRMC +$0.27),
- Agenus (AGEN +$0.16),
- Generation BIO (GBIO +$0.14),
- Compass Therapeutics (CMPX +$0.13),
- Solid Biosciences (SLDB +$0.06),
- Fate therapeutics (FATE +$0.04T
- Editas Medicine (EDIT +$0.04),
Q2/23 – July
- Wednesday closed negative with 13 incliners, 22 decliners and 0 flat
- Tuesday was a holiday
- Monday was a vacation day closing positive with 20 incliners, 13 decliners and 2 flats
The BOTTOM LINE: I try to keep it simple … and short!
I follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”
The market and the cell and gene therapy sector closed lower on Wednesday as traders <partially> returned from the July 4 holiday break with renewed worries about potential interest rate increases from the Fed.
The Federal Reserve released minutes from Federal Open Market Committee's June meeting that showed almost all policymakers opted for the June rate-hike pause and that a July increase was on the table.
Odds of a 25-basis point increase were at 88.7%, according to CME FedWatch Tool.
The coming issue is Q2 reporting is weeks if not a month away.
Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”
Unresolved issues affecting our perception of markets and the factors controlling them --- a dime sized coke bag in the West Wing of the White House, political investigation of the White House and the Bidens, future rate increases, escalation of the Ukraine war, a Russia uncertainty after a on mercenary versus Russia fight and the major issue - recession - US and global could freezing investors' mood.
The top three (3) performing in the session:
· Wednesday: Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS) and CRISPR Therapeutics (CRSP)
· Tuesday was a holiday
· Monday: was a vacation day
While The worst three (3) in the session:
· Wednesday: Blueprint Medicine (BPMC), Vericel (VCEL) and BioLife Solutions (BLFS)
· Tuesday: was a holiday
· Monday: was a vacation day
WHY (?) do I keep posting, so investors can get a daily update of the sector's share pricing and some individual companies TRUTHS while electronic trading chews on our portfolio edges.
I am definitely considered a contrarian depending on the session – one has to be a watcher of the ups and downs as well as measurer of sentiment. I am also a NO trust investor but, a validate and verify journalist/analyst.
The NO spin zone! U.S. public shareholders deserve accountability …
Biostage (OTCQB: BSTG) … so many issues from the past as many of those “miscreant management” members are still employed!
Wednesday closed flat to $3.97 with1 share traded after Tuesday was a holiday, Monday closed up +$0.32 with 200 shares traded, Friday closed down -$0.1365 with 762 shares traded after Thursday closed FLAT with 0 shares traded and last Wednesday closed up +$0.02 with 425 shares traded, <3-month average = 780 shares>
· Question: Review the number of shares traded on a weekly and monthly basis … is OTCQB: BSTG a Ponzi scheme (with their pump/promote buy and sell agenda) as shares are bought to replace those sold?
· Accumulated deficit: $85,901 M – still NO product in sight – a 4-to-5-year clinical trial BEFORE they can evolve to a pediatric protocol!
· OTCQB: BSTG is holding their annual meeting on 7/19, to vote the Beijing, China designated directors …??? Certainly NOT a US company ANYMORE!
My question that resounds, that should be asked is how many companies are at the end of sentiments … leash?
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
